Pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (AS1404), a novel vascular disrupting agent, in phase I clinical trial

Cancer Chemotherapy and Pharmacology

Volumn 59, Issue 5, 2007, Pages 681-687

  Jameson, M B ^a,b,e   Baguley, B C ^b   Kestell, P ^b   Zhao, L ^b   Paxton, J W ^c   Thompson, P I ^a   Waller, S ^d  

^a AUCKLAND CITY HOSPITAL   (New Zealand)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

^c UNIVERSITY OF AUCKLAND   (New Zealand)

^d IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^e WAIKATO HOSPITAL   (New Zealand)

Author keywords

DMXAA; Non linear; Pharmacokinetic; Phase I; Protein binding

Indexed keywords

5,6 DIMETHYLXANTHENONE 4 ACETIC ACID; ALBUMIN; AS 1404; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ARTICLE; CANCER PATIENT; CLINICAL TRIAL; DRUG DOSE ESCALATION; DRUG ELIMINATION; DRUG HYDROXYLATION; DRUG MEGADOSE; GLUCURONIDATION; HUMAN; MAJOR CLINICAL STUDY; MAXIMUM TOLERATED DOSE; MULTIPLE CYCLE TREATMENT; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; AREA UNDER CURVE; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; HALF-LIFE; HUMANS; LINEAR MODELS; NONLINEAR DYNAMICS; XANTHONES;

EID: 33847157946     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-006-0322-6     Document Type: Article

References (30)

1. Akaike H (1974) A new look at the statistical model identification. IEEE Trans Automatic Control 19:716-723
2. Baguley BC, Ching LM (1997) Immunomodulatory actions of xanthenone anticancer agents. BioDrugs 8:119-127
3. Baguley B, Jameson M, Zhao L, Dunlop I, Kestell P (1998) Implications of the albumin binding properties of the anticancer drug 5,6-dimethylxanthenone-4- acetic acid (DMXAA) to its clinical trial. Proc Aust Soc Clin Exp Pharmacol Toxicol 5:208a
4. Chabot GG, Bissery MC, Corbett TC, Rutkowski K, Baker LH (1989) Pharmacodynamics and causes of dose-dependent pharmacokinetics of flavone-8-acetic acid (LM-975; NSC-347512) in mice. Cancer Chemother Pharmacol 24:15-22
5. Ching LM, Joseph WR, Crosier KE, Baguley BC (1994) Induction of tumor necrosis factor-alpha messenger RNA in human and murine cells by the flavone acetic acid analogue 5,6-dimethylxanthenone-4-acetic acid (NSC 640488). Cancer Res 54:870-872
6. Cummings J, Double JA, Bibby MC, Farmer P, Evans S, Kerr DJ, Kaye SB, Smyth JF (1989) Characterization of the major metabolites of flavone acetic acid and comparison of their disposition in humans and mice. Cancer Res 49:3587-3593
7. Damia G, Freschi A, Sorio R, Braida A, Caruso G, Quaia M, Monfardini S, Dincalci M (1990) Flavone acetic acid distribution in human malignant tumors. Cancer Chemother Pharmacol 26:67-70
8. de Forni M, Chabot GG, Armand JP, Gouyette A, Klink-Alak M, Recondo G (1995) Phase I and pharmacology study of flavone acetic acid administered two or three times weekly without alkalinization. Cancer Chemother Pharmacol 35:219-224
9. Gouyette A, Kerr DJ, Kaye SB, Setanoians A, Cassidy J, Bradley C, Forrest G, Soukop M (1988) Flavone acetic acid: a nonlinear pharmacokinetic model. Cancer Chemother Pharmacol 22:114-119
10. Jameson MB, Thompson PI, Baguley BC, Evans BD, Harvey VJ, Porter DJ, McCrystal MR, Small M, Bellenger K, Gumbrell L, Halbert GW, Kestell P (2003) Clinical aspects of a phase I trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent. Br J Cancer 88:1844-1850
11. Kerr DJ, Kaye SB (1989) Flavone acetic acid - preclinical and clinical activity. Eur J Cancer Clin Oncol 25:1271-1272
12. Kerr DJ, Kaye SB, Cassidy J, Bradley C, Rankin E, Adams L, Setanoians A, Young T, Forrest G, Soukop M, Clavel M (1987) Phase I and pharmacokinetic study of flavone acetic acid. Cancer Res 47:6776-6781
13. Kestell P, Paxton JW, Rewcastle GW, Dunlop I, Baguley BC (1999) Plasma disposition, metabolism and excretion of the experimental antitumour agent 5,6-dimethylxanthenone-4-acetic acid in the mouse, rat and rabbit. Cancer Chemother Pharmacol 43:323-330
14. Kestell P, Zhao L, Baguley BC, Palmer BD, Muller G, Paxton JW, Ching LM (2000) Modulation of the pharmacokinetics of the antitumour agent 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in mice by thalidomide. Cancer Chemother Pharmacol 46:135-141
15. Maughan TS, Ward R, Dennis I, Honess DJ, Workman P, Bleehen NM (1992) Tumour concentrations of flavone acetic acid (FAA) in human melanoma - comparison with mouse data. Br J Cancer 66:579-582
16. McKeage MJ, Kestell P, Denny WA, Baguley BC (1991) Plasma pharmacokinetics of the antitumour agents 5,6-dimethylxanthenone-4-acetic acid, xanthenone-4-acetic acid and flavone-8-acetic acid in mice. Cancer Chemother Pharmacol 28:409-413
17. Miners JO, Valente L, Lillywhite KJ, Mackenzie PI, Burchell B, Baguley BC, Kestell P (1997) Preclinical prediction of factors influencing the elimination of 5,6-dimethylxanthenone-4-acetic acid, a new anticancer drug. Cancer Res 57:284-289
18. Olver IN, Webster LK, Bishop JF, Stokes KH (1992) A phase I and pharmacokinetic study of 12-h infusion of flavone acetic acid. Cancer Chemother Pharmacol 29:354-360
19. Rewcastle GW, Kestell P, Baguley BC, Denny WA (1990) Light-induced breakdown of flavone acetic acid and xanthenone analogues in solution. J Natl Cancer Inst 82:528-529
20. Rewcastle GW, Atwell GJ, Li ZA, Baguley BC, Denny WA (1991) Potential antitumor agents. 61. Structure-activity relationships for in vivo colon 38 activity among disubstituted 9-oxo-9h-xanthene-4-acetic acids. J Med Chem 34:217-222
21. Rustin GJ, Bradley C, Galbraith S, Stratford M, Loadman P, Waller S, Bellenger K, Gumbrell L, Folkes L, Halbert G (2003) 5,6-Dimethylxanthenone-4- acetic acid (DMXAA), a novel antivascular agent: phase I clinical and pharmacokinetic study. Br J Cancer 88:1160-1167
22. Webster LK, Ellis AG, Kestell P, Rewcastle GW (1995) Metabolism and elimination of 5,6-dimethylxanthenone-4-acetic acid in the isolated perfused rat liver. Drug Metab Dispos 23:363-368
23. Weiss RB, Green RF, Knight RD, Collins JM, Pelosi JJ, Sulkes A, Curt GA (1988) Phase I and clinical pharmacology study of intravenous flavone acetic acid (NSC 347512). Cancer Res 48:5878-5882
24. Yamaoka K, Nakagawa T, Uno T (1978) Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations. J Pharmacokinet Biopharm 6:165-175
25. Zaharko DS, Grieshaber CK, Plowman J, Cradock JC (1986) Therapeutic and pharmacokinetic relationships of flavone acetic acid: an agent with activity against solid tumors. Cancer Treat Rep 70:1415-1421
26. Zhou S, Paxton JW, Tingle MD, Kestell P (2000) Identification of the human liver cytochrome P450 isoenzyme responsible for the 6-methylhydroxylation of the novel anticancer drug 5,6-dimethylxanthenone-4-acetic acid. Drug Metab Dispos 28:1449-1456
27. Zhou S, Paxton JW, Kestell P, Tingle MD (2001) Reversible binding of the novel anti-tumour agent 5,6-dimethylxanthenone-4-acetic acid to plasma proteins and its distribution into blood cells in various species. J Pharm Pharmacol 53:463-471
28. Zhou S, Kestell P, Paxton JW (2002) Predicting pharmacokinetics and drug interactions in patients from in vitro and in vivo models: the experience with 5,6-dimethylxanthenone-4-acetic acid (DMXAA), an anti-cancer drug eliminated mainly by conjugation. Drug Metab Rev 34:751-790
29. Zhou S, Kestell P, Baguley BC, Paxton JW (2003) Preclinical factors influencing the relative contributions of phase I and II enzymes to the metabolism of the experimental anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid. Biochem Pharmacol 65:109-120
30. Zhou S, Feng X, Kestell P, Baguley BC, Paxton JW (2004) Determination of the investigational anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid and its acyl glucuronide in Caco-2 monolayers by liquid chromatography with fluorescence detection: application to transport studies. J Chromatogr B Analyt Technol Biomed Life Sci 809:87-97